Answers are grounded in this paper and cite their sources.
In vivo study shows CAR-T cell survival relies on IL-2 in tumor microenvironment, indicating adaptation strategies are essential.
Description Chimeric antigen receptor T (CAR-T) cell therapy can lead to durable responses in patients with some hematologic malignancies yet remains largely ineffective in solid tumors. Impaired persistence of CAR-T cells and the immunosuppressive tumor microenvironment (TME) are important barriers to overcome to improve efficacy against solid tumors. To test how T cell mode of tumor recognition affects fate and persistence, we developed a tumor model to compare tumor-specific CAR-T cells and T cells with a transgenic T cell receptor (TCR) side-by-side. While these cells had similar survival and proliferative capacity in vitro, CD8 CAR-T cells had a survival disadvantage in vivo compared to TCR-T cells in the same TME, suggesting that CAR expression reduced CD8 T cell fitness in the TME. To probe regulators of CAR-T cell survival, we used an in vivo CRISPR screen of cell death-related genes. Deletion of Il2ra gave CAR-T cells a fitness disadvantage in vitro but those CAR-T cells ultimately had a fitness advantage in vivo in the TME. This may be due to attenuation of strong IL-2 signaling in vitro, suggesting the possibility that CAR-T cells become dependent on IL-2 for survival during in vitro expansion and this leads to impaired survival upon transfer in vivo where IL-2 can be limiting. Future studies will investigate IL-2 signaling and metabolic dependencies of CAR-T cells, with the goal of identifying strategies to mitigate this dependency and improve survival and function in vivo.
No takes yet. Share an insight, caveat, or question.
Hathaway et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: